Condition: Human Immunodeficiency Virus (HIV)-1 Infection · HIV-1 Subtype A6 Infection · HIV-1 Subtype B Infection · Sponsor: Pomeranian Medical University Szczecin
This study evaluates the real-world effectiveness and safety of a long-acting injectable HIV treatment consisting of cabotegravir and rilpivirine in people living with HIV-1. The focus is on individuals with HIV-1 subtype A6, which is common in Eastern Europe and among people who acquired HIV in that region, and on comparison with individuals with subtype B and those with an unknown subtype. Although long-acting cabotegravir and rilpivirine are widely used and effective, limited real-world data are available on how well this treatment works in people with HIV-1 subtype A6. This is important because subtype A6 has been suggested as a potential risk factor for treatment failure, but current evidence is inconclusive. The study uses existing medical records from treatment centers in Poland, Germany, and the Czech Republic. It includes adults with HIV who have received at least one injection of long-acting cabotegravir and rilpivirine and follows their clinical outcomes for up to 24 months. Researchers will assess viral suppression, treatment persistence, adherence to injection schedules, and reasons for treatment discontinuation. The results of this study will help clinicians better understand whether HIV-1 subtype A6 affects treatment outcomes and whether knowing a patient's HIV subtype is important when deciding to switch to long-acting injectable therapy. The findings may support safer and more effective use of this treatment in diverse patient populations.
This description comes directly from the study's public registry record.
Miłosz Parczewski, prof. dr hab. n. med. · +48 91 813 94 41 · klinzak@pum.edu.pl
Karolina Sorbian-Gajewska
Always discuss trial participation with your own doctor first.
| Hospital Na Bulovce Praque HIV Centre, Department of Infectious Diseases | Prague, Czechia | Recruiting |
| MainFachArzt | Frankfurt, Germany | Recruiting |
| Katedra Chorób Zakaźnych i Niedoborów Immunologicznych | Szczecin, West Pomeranian Voivodeship, Poland | Not Yet Recruiting |
| Wojewódzki Szpital Obserwacyjno-Zakaźny | Bydgoszcz, Poland | Recruiting |
| Szpitale Pomorskie | Gdansk, Poland | Recruiting |
| Wojewódzki Szpital Zakaźny w Warszawie | Warsaw, Poland | Recruiting |
| Wrocławskie Centrum Zdrowia | Wroclaw, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07370649